Loss of inhibitor of growth (ING-4) is implicated in the pathogenesis and progression of human astrocytomas

Brain Pathology

Volumn 20, Issue 2, 2010, Pages 490-497

  Klironomos, George ^a,b   Bravou, Vasiliki ^a   Papachristou, Dionysios J ^a,c   Gatzounis, George ^b   Varakis, John ^a   Parassi, Ekaterini ^d   Repanti, Maria ^e   Papadaki, Helen ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d Nikaia Hospital   (Greece)

^e UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

Author keywords

Human astrocytomas; ING 4; NF B

Indexed keywords

GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SYNAPTOTAGMIN I; UROKINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER INVASION; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENE LOSS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INHIBITOR OF GROWTH 4 GENE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASTROCYTOMA; BRAIN; BRAIN NEOPLASMS; CELL CYCLE PROTEINS; CELL NUCLEUS; CHILD; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NF-KAPPA B; TUMOR SUPPRESSOR PROTEINS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 75949101066     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2009.00325.x     Document Type: Article

References (45)

1. Aasland R, Gibson TJ, Stewart AF (1995) The PHD finger: implications for chromatin-mediated transcriptional regulation. Trends Biochem Sci 20 : 56 59.
2. Baldwin AS Jr. (2001) Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 107 : 3 6.
3. Birkedal-Hansen H (1995) Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 7 : 728 735.
4. Bjorklund M, Koivunen E (2005) Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 1755 : 37 69.
5. Brat DJ, Bellail AC, Van Meir EG (2005) The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol 7 : 122 133.
6. Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J (1993) Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 85 : 574 578.
7. Campos EI, Chin MY, Kuo WH, Li G (2004) Biological functions of the ING family tumor suppressors. Cell Mol Life Sci 61 : 2597 2613.
8. Choe G, Park JK, Jouben-Steele L, Kremen TJ, Liau LM, Vinters HV et al (2002) Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res 8 : 2894 2901.
9. Coles AH, Jones SN (2009) The ING gene family in the regulation of cell growth and tumorigenesis. J Cell Physiol 218 : 45 57.
10. Colla S, Tagliaferri S, Morandi F, Lunghi P, Donofrio G, Martorana D et al (2007) The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. Blood 110 : 4464 4475.
11. Das R, Philip S, Mahabeleshwar GH, Bulbule A, Kundu GC (2005) Osteopontin: its role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression. IUBMB Life 57 : 441 447.
12. Feng X, Hara Y, Riabowol K (2002) Different HATS of the ING1 gene family. Trends Cell Biol 12 : 532 538.
13. Garkavtsev I, Kozin SV, Chernova O, Xu L, Winkler F, Brown E et al (2004) The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 428 : 328 332.
14. Gondi CS, Rao JS (2009) Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metalloproteinases. Methods Mol Biol 487 : 267 281.
15. Gunduz M, Magatsuka H, Demiran K, Gunduz E, Cenqiz B, Ouchida M et al (2005) Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas. Gene 356 : 109 117.
16. Gunduz M, Gunduz E, Rivera RS, Nagatsuka H (2008) The inhibitor of growth (ING) gene family: potential role in cancer therapy. Curr Cancer Drug Targets 8 : 275 284.
17. Han YP, Tuan TL, Wu H, Hughes M, Garner WLTN (2001) F-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated induction of MT1-MMP. J Cell Sci 114 : 131 139.
18. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ (2001) Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20 : 4188 4197.
19. Janicke F, Schmitt M, Ulm K, Gossner W, Graeff H (1989) Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 2 : 1049.
20. Kim HJ, Hawke N, Baldwin AS (2006) NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ 13 : 738 747.
21. Kim S, Chin K, Gray JW, Bishop JM (2004) A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancer. Proc Natl Acad Sci USA 101 : 16251 16256.
22. Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH (2007) Inhibition of angiogenesis and invasion by 3,3′-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 67 : 3310 3319.
23. Korkolopoulou P, Levidou G, Saetta AA, Habr EI, Eftichiadis C, Demenagas P et al (2008) Expression of nuclear factor-kappaB in human astrocytomas: relation to pI kappa Ba, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival. Hum Pathol 39 : 1143 1152.
24. Lee CH, Jeon YT, Kim SH, Song YS (2007) NF-kappaB as a potential molecular target for cancer therapy. Biofactors 29 : 19 35.
25. Lefranc F, Brotchi J, Kiss R (2005) Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 23 : 2411 2422.
26. Li J, Martinka M, Li G (2008) Role of ING4 in human melanoma cell migration, invasion and patient survival. Carcinogenesis 29 : 1373 1379.
27. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM et al (2003) Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer 105 : 735 746.
28. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114 : 97 109.
29. Mignatti P, Rifkin DB (1993) Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73 : 161 195.
30. Mott JD, Werb Z (2004) Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16 : 558 564.
31. Nakada M, Nakamura H, Ikeda E, Fujimoto N, Yamashita J, Sato H et al (1999) Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 154 : 417 428. (Pubitemid 29094092)
32. Novak U, Cocks BG, Hamilton JA (1991) A labile repressor acts through the NFkB-like binding sites of the human urokinase gene. Nucleic Acids Res 19 : 3389 3393.
33. Perkins ND (2004) NF-kappaB tumor promoter or suppressor? Trends Cell Biol 14 : 64 69.
34. Raithatha SA, Muzik H, Muzik H, Rewcastle NB, Johnston RN, Edwards DR et al (2000) Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas. Neuro-oncol 2 : 145 150.
35. Rao JS (2003) Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3 : 489 501.
36. Raychaudhuri B, Han Y, Lu T, Vogelbaum MA (2007) Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype. J Neurooncol 85 : 39 47.
37. Reuning U, Wilhelm O, Nishiguchi T, Guerrini L, Blasi F, Graeff H et al (1995) Inhibition of NF-kappa B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1. Nucleic Acids Res 23 : 3887 3893.
38. Sappino AP, Busso N, Belin D, Vassalli JD (1987) Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res 47 : 4043 4046.
39. Sawaya R, Ramo OJ, Shi ML, Mandybur G (1991) Biological significance of tissue plasminogen activator content in brain tumors. J Neurosurg 74 : 480 486.
40. Sliva D (2004) Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr Cancer Drug Targets 4 : 327 336.
41. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T (2003) Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 89 : 1270 1275. (Pubitemid 37363416)
42. Unoki M, Shen JC, Zheng ZM, Harris CC (2006) Novel splice variants of ING4 and their possible roles in the regulation of cell growth and motility. J Biol Chem 281 : 34677 34686.
43. Vincenti MP, Coon CI, Brinckerhoff CE (1998) Nuclear factor kappaB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1beta-stimulated synovial fibroblasts. Arthritis Rheum 41 : 1987 1994.
44. Wang W, Abbruzzese JL, Evans DB, Chiao PJ (1999) Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene 18 : 4554 4563.
45. Wu JM, Sheng H, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu M et al (2009) NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett 278 : 145 155.